Unknown

Dataset Information

0

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.


ABSTRACT: Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.

SUBMITTER: Turner PJ 

PROVIDER: S-EPMC7857113 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9011687 | biostudies-literature
| S-EPMC8047300 | biostudies-literature
| S-EPMC8577302 | biostudies-literature
| S-EPMC8255352 | biostudies-literature
| S-EPMC3983904 | biostudies-other
2022-10-14 | PXD031969 | Pride
| S-SCDT-EMM-2021-15227 | biostudies-other
| S-EPMC9695423 | biostudies-literature